LianBio【LIANY】

時価総額

$1783万

PER

アジア向けに医薬品を導入・開発する臨床段階のバイオ医薬品企業の新興企業。心血管・腫瘍・眼科・炎症で8候補と3件のレジスト試験を展開。21年11月の米国上場と23年2月のオミランコルのライセンス契約締結。中国・アジア太平洋・米国で展開。

	2021年 12月31日	2022年 12月31日
Net Loss	-196	-110
Non-cash share consideration, issued in acquisition of IPR&D	9	-
Non-cash operating lease expense (benefit)	-0	0
Depreciation	1	1
Share based compensation expense	9	19
Amortization of discounts on investments, net	0	2
Unrealized foreign currency transaction loss, net	-0	-0
Non-cash consideration relating to Pfizer Commercial Agreement	-	20
Non Cash Write Off Of Notes Payable	-	4
Decrease (increase) in prepaid expenses and other current assets	8	-1
(Increase) decrease in other receivable	-14	1
Decrease (increase) in other non-current assets	0	-0
Decrease in accounts payable	-2	-2
Increase in accrued expenses	9	10
(Decrease) increase in other current liabilities	1	-0
Net cash used in operating activities	-164	-99
Purchase of property and equipment	1	2
Purchase of marketable securities	155	303
Sales and redemptions of marketable securities	-	236
Net cash used for investing activities	-156	-69
Proceeds from Stock Options Exercised	6	2
Proceeds from Issuance Initial Public Offering	311	-
Proceeds from Issuance of Redeemable Convertible Preferred Stock	3	-
Net cash provided by financing activities	313	2
Effect of exchange rate changes on cash and cash equivalents	0	-2
Net decrease in cash, cash equivalents and restricted cash	-6	-169
Income Taxes Paid, Net	-	0
Right-of-use assets obtained in exchange for lease obligations	5	1
Payment Of Milestone Amount	-	2
Deferred Offering Costs Incurred But Not Yet Paid	1	-
Capital Expenditures Incurred but Not yet Paid	1	1
Conversion of Preferred Shares	353	-
Conversion of Warrants	10	-